Does valproic acid or levetiracetam improve survival in Glioblastoma?: a pooled analysis of prospective clinical trials in newly diagnosed glioblastoma
PurposeSymptomatic epilepsy is a common complication of glioblastoma and requires pharmacotherapy. Several uncontrolled retrospective case series and a post hoc analysis of the registration trial for temozolomide indicated an association between valproic acid (VPA) use and improved survival outcomes...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
January 19, 2016
|
| In: |
Journal of clinical oncology
Year: 2016, Volume: 34, Issue: 7, Pages: 731-739 |
| ISSN: | 1527-7755 |
| DOI: | 10.1200/JCO.2015.63.6563 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1200/JCO.2015.63.6563 Verlag, lizenzpflichtig, Volltext: https://ascopubs.org/doi/10.1200/JCO.2015.63.6563 
|
| Author Notes: | Caroline Happold, Thierry Gorlia, Olivier Chinot, Mark R. Gilbert, L. Burt Nabors, Wolfgang Wick, Stephanie L. Pugh, Monika Hegi, Timothy Cloughesy, Patrick Roth, David A. Reardon, James R. Perry, Minesh P. Mehta, Roger Stupp, Michael Weller |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1696930359 | ||
| 003 | DE-627 | ||
| 005 | 20230427121943.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200430s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/JCO.2015.63.6563 |2 doi | |
| 035 | |a (DE-627)1696930359 | ||
| 035 | |a (DE-599)KXP1696930359 | ||
| 035 | |a (OCoLC)1341317739 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Happold, Caroline Juliette |d 1979- |e VerfasserIn |0 (DE-588)132931516 |0 (DE-627)528685708 |0 (DE-576)264306678 |4 aut | |
| 245 | 1 | 0 | |a Does valproic acid or levetiracetam improve survival in Glioblastoma? |b a pooled analysis of prospective clinical trials in newly diagnosed glioblastoma |c Caroline Happold, Thierry Gorlia, Olivier Chinot, Mark R. Gilbert, L. Burt Nabors, Wolfgang Wick, Stephanie L. Pugh, Monika Hegi, Timothy Cloughesy, Patrick Roth, David A. Reardon, James R. Perry, Minesh P. Mehta, Roger Stupp, Michael Weller |
| 264 | 1 | |c January 19, 2016 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 30.04.2020 | ||
| 520 | |a PurposeSymptomatic epilepsy is a common complication of glioblastoma and requires pharmacotherapy. Several uncontrolled retrospective case series and a post hoc analysis of the registration trial for temozolomide indicated an association between valproic acid (VPA) use and improved survival outcomes in patients with newly diagnosed glioblastoma.Patients and MethodsTo confirm the hypothesis suggested above, a combined analysis of survival association of antiepileptic drug use at the start of chemoradiotherapy with temozolomide was performed in the pooled patient cohort (n = 1,869) of four contemporary randomized clinical trials in newly diagnosed glioblastoma: AVAGlio (Avastin in Glioblastoma; NCT00943826), CENTRIC (Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status; NCT00689221), CORE (Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status; NCT00813943), and Radiation Therapy Oncology Group 0825 (NCT00884741). Progression-free survival (PFS) and overall survival (OS) were compared between: (1) any VPA use and no VPA use at baseline or (2) VPA use both at start of and still after chemoradiotherapy. Results of Cox regression models stratified by trial and adjusted for baseline prognostic factors were analyzed. The same analyses were performed with levetiracetam (LEV).ResultsVPA use at start of chemoradiotherapy was not associated with improved PFS or OS compared with all other patients pooled (PFS: hazard ratio [HR], 0.91; 95% CI, 0.77 to 1.07; P = .241; OS: HR, 0.96; 95% CI, 0.80 to 1.15; P = .633). Furthermore, PFS and OS of patients taking VPA both at start of and still after chemoradiotherapy were not different from those without antiepileptic drug use at both time points (PFS: HR, 0.92; 95% CI, 0.74 to 1.15; P = .467; OS: HR, 1.10; 95% CI, 0.86 to 1.40; P = .440). Similarly, no association with improved outcomes was observed for LEV use.ConclusionThe results of this analysis do not justify the use of VPA or LEV for reasons other than seizure control in patients with newly diagnosed glioblastoma outside clinical trials. | ||
| 700 | 1 | |a Gorlia, Thierry |e VerfasserIn |4 aut | |
| 700 | 1 | |a Chinot, Olivier |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gilbert, Mark R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Nabors, L. Burt |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wick, Wolfgang |d 1970- |e VerfasserIn |0 (DE-588)120297736 |0 (DE-627)080586929 |0 (DE-576)186221320 |4 aut | |
| 700 | 1 | |a Pugh, Stephanie L. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hegi, Monika |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cloughesy, Timothy |e VerfasserIn |4 aut | |
| 700 | 1 | |a Roth, Patrick |e VerfasserIn |4 aut | |
| 700 | 1 | |a Reardon, David A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Perry, James R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mehta, Minesh P. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Stupp, Roger |e VerfasserIn |4 aut | |
| 700 | 1 | |a Weller, Michael |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical oncology |d Alexandria, Va. : American Society of Clinical Oncology, 1983 |g 34(2016), 7, Seite 731-739 |h Online-Ressource |w (DE-627)313116962 |w (DE-600)2005181-5 |w (DE-576)090887018 |x 1527-7755 |7 nnas |a Does valproic acid or levetiracetam improve survival in Glioblastoma? a pooled analysis of prospective clinical trials in newly diagnosed glioblastoma |
| 773 | 1 | 8 | |g volume:34 |g year:2016 |g number:7 |g pages:731-739 |g extent:9 |a Does valproic acid or levetiracetam improve survival in Glioblastoma? a pooled analysis of prospective clinical trials in newly diagnosed glioblastoma |
| 856 | 4 | 0 | |u https://doi.org/10.1200/JCO.2015.63.6563 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://ascopubs.org/doi/10.1200/JCO.2015.63.6563 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200430 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 120297736 |a Wick, Wolfgang |m 120297736:Wick, Wolfgang |d 910000 |d 911100 |e 910000PW120297736 |e 911100PW120297736 |k 0/910000/ |k 1/910000/911100/ |p 6 | ||
| 999 | |a KXP-PPN1696930359 |e 3646399783 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"subtitle":"a pooled analysis of prospective clinical trials in newly diagnosed glioblastoma","title_sort":"Does valproic acid or levetiracetam improve survival in Glioblastoma?","title":"Does valproic acid or levetiracetam improve survival in Glioblastoma?"}],"physDesc":[{"extent":"9 S."}],"relHost":[{"title":[{"title":"Journal of clinical oncology","title_sort":"Journal of clinical oncology","subtitle":"JCO : an American Society of Clinical Oncology journal"}],"titleAlt":[{"title":"official journal of the American Society of Clinical Oncology"},{"title":"JCO"},{"title":"Journal of clinical oncology legacy archive (ASCO)"}],"note":["Fortsetzung der Druck-Ausgabe","Gesehen am 22.05.23"],"pubHistory":["1.1983 -"],"corporate":[{"display":"American Society of Clinical Oncology","role":"isb"}],"origin":[{"publisher":"American Society of Clinical Oncology ; Lippincott Williams & Wilkins","dateIssuedDisp":"1983-","publisherPlace":"Alexandria, Va. ; Baltimore, Md. [u.a.]","dateIssuedKey":"1983"}],"disp":"Does valproic acid or levetiracetam improve survival in Glioblastoma? a pooled analysis of prospective clinical trials in newly diagnosed glioblastomaJournal of clinical oncology","id":{"eki":["313116962"],"zdb":["2005181-5"],"issn":["1527-7755"]},"physDesc":[{"extent":"Online-Ressource"}],"part":{"extent":"9","issue":"7","year":"2016","pages":"731-739","volume":"34","text":"34(2016), 7, Seite 731-739"},"language":["eng"],"type":{"media":"Online-Ressource","bibl":"periodical"},"recId":"313116962"}],"person":[{"role":"aut","family":"Happold","display":"Happold, Caroline Juliette","given":"Caroline Juliette"},{"given":"Thierry","display":"Gorlia, Thierry","role":"aut","family":"Gorlia"},{"given":"Olivier","display":"Chinot, Olivier","family":"Chinot","role":"aut"},{"given":"Mark R.","family":"Gilbert","role":"aut","display":"Gilbert, Mark R."},{"given":"L. Burt","display":"Nabors, L. Burt","family":"Nabors","role":"aut"},{"role":"aut","family":"Wick","display":"Wick, Wolfgang","given":"Wolfgang"},{"given":"Stephanie L.","display":"Pugh, Stephanie L.","family":"Pugh","role":"aut"},{"given":"Monika","display":"Hegi, Monika","family":"Hegi","role":"aut"},{"family":"Cloughesy","role":"aut","display":"Cloughesy, Timothy","given":"Timothy"},{"given":"Patrick","display":"Roth, Patrick","family":"Roth","role":"aut"},{"display":"Reardon, David A.","role":"aut","family":"Reardon","given":"David A."},{"given":"James R.","family":"Perry","role":"aut","display":"Perry, James R."},{"display":"Mehta, Minesh P.","family":"Mehta","role":"aut","given":"Minesh P."},{"display":"Stupp, Roger","role":"aut","family":"Stupp","given":"Roger"},{"family":"Weller","role":"aut","display":"Weller, Michael","given":"Michael"}],"language":["eng"],"note":["Gesehen am 30.04.2020"],"origin":[{"dateIssuedDisp":"January 19, 2016","dateIssuedKey":"2016"}],"name":{"displayForm":["Caroline Happold, Thierry Gorlia, Olivier Chinot, Mark R. Gilbert, L. Burt Nabors, Wolfgang Wick, Stephanie L. Pugh, Monika Hegi, Timothy Cloughesy, Patrick Roth, David A. Reardon, James R. Perry, Minesh P. Mehta, Roger Stupp, Michael Weller"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"recId":"1696930359","id":{"doi":["10.1200/JCO.2015.63.6563"],"eki":["1696930359"]}} | ||
| SRT | |a HAPPOLDCARDOESVALPRO1920 | ||